Iluvien

Type: Product
Name: Iluvien
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

pSivida Posts 4th Quarter and FY 2014 Results

pSivida reported financial results for its fourth quarter and fiscal year ended June 30. According to a release from the Company, advancing its strategy of becoming a specialty-pharma company, pSivida continued enrollment of the Phase III trial for its ... [Published Individual.com - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Alimera Sciences' ILUVIEN® Receives Tenth National Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema

By a News Reporter-Staff News Editor at Marketing Business Weekly Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, ... [Published Pharmacy Choice - Sep 12 2014]
First reported Sep 09 2014 - Updated Sep 10 2014 - 4 reports

pSivida Corp. Names James Barry to Board of Directors

pSivida Corp. ( NASDAQ: PSDV ) (ASX: PVA), a leader in developingsustained release, drug delivery products for treatment ofback-of-the-eye diseases, announced today that it has elected James J.Barry, Ph.D. to its Board of Directors.Dr. Barry, age 55, ... [Published RCL Advisors - Sep 10 2014]
First reported Sep 08 2014 - Updated Sep 08 2014 - 1 reports

pSivida: Swedish Medical Products Agency Grants Marketing Authorization for Iluvien

pSivida Corp. reported that the Swedish Medical Products Agency granted marketing authorization to Iluvien for the treatment of vision impairment associated with chronic diabetic macular edema considered insufficiently responsive to available therapies. ... [Published Individual.com - Sep 08 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 10 reports

Alimera's ILUVIEN secures Swedish marketing authorization to treat chronic DME

Alimera Sciences has received marketing authorization from the Swedish Medical Products Agency for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME). ... [Published PBR - News - Sep 04 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Sweet News For ABT, Adherex To Change Name, FLXN's Work In Progress, INFI Rises

Abbott's (ABT: Quote) revolutionary new glucose sensing technology for people with diabetes, FreeStyle Libre Flash Glucose Monitoring System, has received CE Mark (Conformite Europeenne).The FreeStyle Libre reads glucose levels through a sensor that can ... [Published RTTNews.com - Sep 04 2014]
First reported Aug 26 2014 - Updated Aug 26 2014 - 1 reports

Your September Biotech Back-to-School Calendar

08/26/14 - 09:50 AM EDTBOSTON ( TheStreet ) -- If you're like me, a dad with school-age kids, September is a real page turner in the calendar. Everyone gets a fresh start on January 1, but Labor Day serves the same purpose. The lazy days of summer are ... [Published TheStreet.com - Aug 26 2014]
First reported Aug 22 2014 - Updated Aug 23 2014 - 1 reports

Alimera Sciences reports net income for Q2

Alimera Sciences, Inc., a biopharmaceutical company, has reported that net income applicable to common stockholders for the second quarter ended June 30, 2014 was $1.12 million, or $0.16 per diluted share, compared to a net loss applicable to common stockholders ... [Published Individual.com - Aug 22 2014]
First reported Jul 31 2014 - Updated Aug 01 2014 - 3 reports

Alimera' ILUVIEN gets marketing authorization in Denmark for DME treatment

US-based biopharmaceutical firm Alimera Sciences has received marketing authorization from the Danish Health and Medicines Authority for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently ... [Published PBR - News - Aug 01 2014]
First reported Jul 28 2014 - Updated Jul 29 2014 - 3 reports

Alimera' ILUVIEN gets marketing authorization in Norway to treat chronic DME

US-based biopharmaceutical firm Alimera Sciences has received marketing authorization from the Norwegian Medicines Evaluation Board for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive ... [Published PBR - News - Jul 29 2014]
First reported Jun 30 2014 - Updated Jul 01 2014 - 4 reports

pSivida Corp. Reports Positive Regulatory Outcome for ILUVIEN®; Moves to National Phase for Marketing Authorizations in 10 More EU Countries

WATERTOWN, Mass.--(EON: Enhanced Online News)--pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the regulatory process for marketing authorizations ... [Published EON Communications - Jun 30 2014]
First reported Jun 23 2014 - Updated Jun 24 2014 - 4 reports

Alimera's ILUVIEN gets marketing authorization in Italy to treat chronic DME

US-based biopharmaceutical firm Alimera Sciences has secured marketing authorization from the Italian Medicines Agency (Agenzia Italiana del Farmaco) for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME) considered ... [Published PBR - News - Jun 24 2014]

Quotes

"We enhanced our liquidity in the last fiscal year with the sale of common stock, ending the year with $18.3 million" concluded Dr. Ashton
...countries to provide their patients with the only three-year treatment for DME," said Dan Myers, Alimera's president and chief executive officer. "We look forward to continuing to expand our geographic presence in Europe through additional national marketing authorizations."
...Iluvien, expanding the potential for its future sales in the EU," said Paul Ashton, president and chief executive officer of pSivida, in a release. "We look forward to the FDA's action on Iluvien. We are entitled to a $25 million milestone payment from our licensee Alimera Sciences upon FDA approval of Iluvien. We are also entitled to share in the net profits from Alimera's sales of Iluvien on a country-by-country basis including in the EU and the U S "
...Net revenue for the six months ended June 30, 2014 was $4.27 million, compared to $179,000 for the same period ended June 30, 2013. "We achieved an important milestone during the second quarter of 2014 as more commercial patients have now been injected with ILUVIEN than were treated in our clinical trials. Further, we experienced a 25% increase in ILUVIEN injections in the UK during the second quarter of 2014 compared to the prior quarter. Our second quarter 2014 revenue from the UK was similar to the first quarter revenue as several hospitals in the UK stocked their pharmacies following the implementation of the NICE guidance for the reimbursement of ILUVIEN in the first quarter 2014" said Dan Myers, president and CEO of Alimera Sciences

More Content

All (69) | News (32) | Reports (0) | Blogs (37) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
pSivida Posts 4th Quarter and FY 2014 Results [Published Individual.com - Sep 15 2014]
Alimera Sciences' ILUVIEN® Receives Tenth Nati... [Published Pharmacy Choice - Sep 12 2014]
pSivida Corp. Names James Barry to Board of Dir... [Published RCL Advisors - Sep 10 2014]
Iluvien approved in 10th EU market: pSivida [Published Australian Life Scientist - Sep 10 2014]
pSivida's (PSDV) CEO Dr. Paul Ashton on Q4 2014... [Published Seeking Alpha - Sep 10 2014]
pSivida Corp. Reports Fourth Quarter and FY 201... [Published Wall Street Select - Sep 09 2014]
pSivida: Swedish Medical Products Agency Grants... [Published Individual.com - Sep 08 2014]
Alimera's ILUVIEN secures Swedish marketing aut... [Published PBR - News - Sep 04 2014]
Sweet News For ABT, Adherex To Change Name, FLX... [Published RTTNews.com - Sep 04 2014]
Alimera Sciences' ILUVIEN Receives Tenth Nation... [Published FirstWord Pharma - Sep 03 2014]
Iluvien granted marketing authorization in Sweden [Published Orthopedics Today - Sep 03 2014]
pSivida Corp. Reports ILUVIEN® for Chronic Diab... [Published Fort Mills Times - Sep 03 2014]
pSivida Corp. Reports ILUVIEN® for Chronic Diab... [Published Digital Journal - Sep 03 2014]
PSivida Corp. Reports ILUVIEN® for Chronic Diab... [Published BusinessWeek - Sep 03 2014]
pSivida Corp. Reports ILUVIEN(R) for Chronic Di... [Published Scottrade - Sep 03 2014]
pSivida Corp. Reports ILUVIEN® for Chronic Diab... [Published Business Wire Health News - Sep 03 2014]
Alimera Sciences' ILUVIEN® Receives Tenth Natio... [Published ADVFN UK - Sep 03 2014]
Alimera Sciences' ILUVIEN® Receives Tenth Natio... [Published PR Newswire: Health - Sep 03 2014]
Your September Biotech Back-to-School Calendar [Published TheStreet.com - Aug 26 2014]
Alimera Sciences reports net income for Q2 [Published Individual.com - Aug 22 2014]
3 smart-money growth stocks to boost your returns [Published Motley Fool - Aug 21 2014]
2nd Half Of 2014 Biotechnology Catalysts--Part 4 [Published Seeking Alpha - Aug 18 2014]
ALIMERA SCIENCES : Reports 2Q Financial Results [Published 4 Traders - Aug 16 2014]
Biotech Stock Directory Update [Published InvestorIdeas.com - Aug 14 2014]
pSivida Corp.: Imminent New Drug Approval, Stea... [Published BioPortfolio - Aug 12 2014]
pSivida Corp.: Imminent New Drug Approval, Stea... [Published Seeking Alpha - Aug 12 2014]
Denmark grants marketing authorisation to Alime... [Published PharmaBiz - Aug 02 2014]
Alimera' ILUVIEN gets marketing authorization i... [Published PBR - News - Aug 01 2014]
pSivida Corp. Reports ILUVIEN® for Chronic Diab... [Published Business Wire Health News - Jul 31 2014]
Alimera Sciences' ILUVIEN® Receives Marketing A... [Published PR Newswire: General Business - Jul 31 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Alimera's ILUVIEN secures Swedish marketing aut... [Published PBR - News - Sep 04 2014]
Alimera Sciences has received marketing authorization from the Swedish Medical Products Agency for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME). ...
pSivida Corp. Reports ILUVIEN® for Chronic Diab... [Published Business Wire Health News - Sep 03 2014]
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida reports ILUVIEN for chronic diabetic macular edema receives marketing authorization in Sweden - 10th EU approval ...
Alimera Sciences' ILUVIEN® Receives Tenth Natio... [Published PR Newswire: Health - Sep 03 2014]
ATLANTA, Sept. 3, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Swedish ...
Alimera' ILUVIEN gets marketing authorization i... [Published PBR - News - Aug 01 2014]
US-based biopharmaceutical firm Alimera Sciences has received marketing authorization from the Danish Health and Medicines Authority for ILUVIEN to treat vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently ...
pSivida Corp. Reports ILUVIEN® for Chronic Diab... [Published Business Wire Health News - Jul 31 2014]
WATERTOWN, Mass.--(BUSINESS WIRE)--pSivida reports Iluvien for Chronic DME receives Marketing Authorization in Denmark, 9th EU approval ...
1 2 3 4 5 6 7 8
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.